bluebird bio (NASDAQ:BLUE – Free Report) had its price target trimmed by Wells Fargo & Company from $3.00 to $2.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has an equal weight rating on the biotechnology company’s stock.
A number of other equities research analysts have also commented on the company. Royal Bank of Canada reissued a sector perform rating and issued a $4.00 price target on shares of bluebird bio in a research report on Thursday, August 15th. Barclays reduced their target price on shares of bluebird bio from $8.00 to $4.00 and set an overweight rating for the company in a research note on Thursday, August 15th. Robert W. Baird dropped their price target on shares of bluebird bio from $7.00 to $6.00 and set an outperform rating on the stock in a research report on Thursday, August 15th. JPMorgan Chase & Co. cut shares of bluebird bio from an overweight rating to a neutral rating in a report on Thursday, August 15th. Finally, Cantor Fitzgerald reiterated a neutral rating on shares of bluebird bio in a research note on Monday, September 16th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of Hold and a consensus price target of $4.63.
View Our Latest Analysis on BLUE
bluebird bio Price Performance
Hedge Funds Weigh In On bluebird bio
Institutional investors and hedge funds have recently bought and sold shares of the company. Ghisallo Capital Management LLC purchased a new position in shares of bluebird bio during the 4th quarter valued at $4,347,000. Vestal Point Capital LP bought a new position in bluebird bio during the fourth quarter worth about $2,967,000. Vanguard Group Inc. boosted its position in bluebird bio by 19.6% during the first quarter. Vanguard Group Inc. now owns 10,498,460 shares of the biotechnology company’s stock worth $13,438,000 after purchasing an additional 1,723,081 shares during the period. HBK Investments L P bought a new stake in shares of bluebird bio in the fourth quarter valued at approximately $2,070,000. Finally, AQR Capital Management LLC raised its position in shares of bluebird bio by 315.3% in the second quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company’s stock valued at $1,223,000 after purchasing an additional 1,013,144 shares during the period. 87.43% of the stock is owned by institutional investors.
About bluebird bio
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.
Read More
- Five stocks we like better than bluebird bio
- Comparing and Trading High PE Ratio Stocks
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- How Can Investors Benefit From After-Hours Trading
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- The Role Economic Reports Play in a Successful Investment Strategy
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.